Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression
MIAMI and PITTSBURGH, June 30, 2022 -- iTolerance, Inc., an early-stage regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression and LyGenesis, Inc., a clinical-stage biotechnology...
iTolerance, Inc. Awarded Industry Discovery and Development Partnership with JDRF for Advanced Pre-Clinical Development of iTOL-100 and iTOL-101 for the Treatment of Type 1 Diabetes
Company advancing development of lead program, iTOL-101, as a potential breakthrough in curing Type 1 Diabetes with the potential to eliminate the need for chronic life-long immunosuppressionThe up to $850,000 award issued to iTolerance was given in furtherance of...
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression
MIAMI and PITTSBURGH, June 30, 2022 -- iTolerance, Inc., an early-stage regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression and LyGenesis, Inc., a clinical-stage biotechnology...
iTolerance, Inc. Awarded Industry Discovery and Development Partnership with JDRF for Advanced Pre-Clinical Development of iTOL-100 and iTOL-101 for the Treatment of Type 1 Diabetes
Company advancing development of lead program, iTOL-101, as a potential breakthrough in curing Type 1 Diabetes with the potential to eliminate the need for chronic life-long immunosuppressionThe up to $850,000 award issued to iTolerance was given in furtherance of...
iTolerance, Inc. Pre-Clinical Non-Human Primate Study Demonstrates Long-Term Success of Allogeneic Islet Implantation Without Chronic Immunosuppression for the Treatment of Diabetes
Data published in peer-reviewed journal, Science AdvancesCo-implantation of allogeneic islets and streptavidin (SA)-FasL-presenting microgels sustained long-term (>6 months) survival of pancreatic islet cells and provided excellent glycemic control in non-human...